<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88B1E177-B3F4-421A-85E1-683228DE3D70"><gtr:id>88B1E177-B3F4-421A-85E1-683228DE3D70</gtr:id><gtr:name>Arizona State University</gtr:name><gtr:address><gtr:line1>PO Box 875603</gtr:line1><gtr:line2>1120 S Cady Mall</gtr:line2><gtr:line3>INDTDSB 366</gtr:line3><gtr:line4>Tempe</gtr:line4><gtr:line5>AZ</gtr:line5><gtr:postCode>85282</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88B1E177-B3F4-421A-85E1-683228DE3D70"><gtr:id>88B1E177-B3F4-421A-85E1-683228DE3D70</gtr:id><gtr:name>Arizona State University</gtr:name><gtr:address><gtr:line1>PO Box 875603</gtr:line1><gtr:line2>1120 S Cady Mall</gtr:line2><gtr:line3>INDTDSB 366</gtr:line3><gtr:line4>Tempe</gtr:line4><gtr:line5>AZ</gtr:line5><gtr:postCode>85282</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/70FC2983-CD4D-4F05-B6F7-DA5E6BE96736"><gtr:id>70FC2983-CD4D-4F05-B6F7-DA5E6BE96736</gtr:id><gtr:firstName>Linda</gtr:firstName><gtr:surname>Dixon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG530468%2F1"><gtr:id>1EA288DC-5992-4891-81EE-A529121923FC</gtr:id><gtr:title>Outpacing infectious diseases: African swine fever virus vaccine development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/G530468/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>30584</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arizona State University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Biodesign Institute</gtr:department><gtr:description>Outpacing Infectious Diseases Collaboration</gtr:description><gtr:id>71CBE6A1-0FD7-436D-99EC-E3DD69D48C37</gtr:id><gtr:impact>The results have led to further funding DEFRA SE1514, SE1515
. BBSRC CIDLID project BB/H008969/1 2010 -2014
An invention disclosure has been filed and patent application is in progress. The project involves molecular biology, virology, immunology, pathogenesis</gtr:impact><gtr:outcomeId>58c18599c84117.85817973-1</gtr:outcomeId><gtr:partnerContribution>Reagents for vaccination experiments were prepared by our collaborators</gtr:partnerContribution><gtr:piContribution>We carried out testing of candidate vaccines for African swine fever virus prepared by Arizona State University</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arizona State University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Arizona State University ASFV vaccine development</gtr:description><gtr:id>58B04DC9-940C-4176-B6BC-E9A47735E2F1</gtr:id><gtr:impact>Patent Application and Publication in progress</gtr:impact><gtr:outcomeId>58c68caa1d0497.46109655-1</gtr:outcomeId><gtr:partnerContribution>Reagents for immunisation of pigs. Expertise on viral vectored vaccines and DNA vaccines</gtr:partnerContribution><gtr:piContribution>Immunisation and challenge of pigs with ASFV. Expertise on ASFV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The work has identified potentially protective African swine fever virus antigens which in future may be incorporated into effective vaccines. No vaccine is currently available.
The genes encoding these antigens have been cloned into DNA plasmids and recombinant vaccinia virus vectors.
A method for delivery of genes to pigs by DNA prime and recombinant vaccinia virus boost has been optimized and will be useful for study of immune responses and design of vaccines for other pig diseases</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>394FB43F-02D8-4207-9E77-0E44774ED05E</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>546b70974ba541.48071079</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Education,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>This project is a partnering award with Prof Bert Jacobs and Dr kathy Sykes, Biodeisgn Institute, Arizona State University. to utse high throughput methods they have developed for cloning and expressing antigens in plasmids and recombinant vaccinia viruses. Using these methods all the genes coded by a strain of ASFV circulating in the caucasus and Russian Federation have been cloned in DNA plasmids and 47 in recombinant vaccinia viruses. A protocol was optimised to immunise pigs with pools of DNA plasmids and boost with recombinant vaccinia viruses. Immune responses to individual antigens was measured using a library of recombinant ASFV antigens. The first results from an immunisation and challenge experiment in pigs indicated that delivery of the 47 antigens reduced the levels of virus in blood and some tissues incluidng spleen. Thus the data suggest that some protective effect was achieved. Further funding was obtained and this has lead identification of 4 novel ASFV antigens that in combination with 4 other ASFV antigens can induce 100% protection in pigs against challenge with virulent virus. A patent application is being prepared.

The project has provided funds to faciltate the collaboration by enabling joint meetings to be conducted.</gtr:description><gtr:exploitationPathways>Potentially protective African swine fever virus antigens have been identified which will be incorporated into vaccine discovery programmes. methods have been developed to deliver pools of DNA plasmids and recombinant vaccinia viruses to pigs. These will be useful for studies with other pig diseases.</gtr:exploitationPathways><gtr:id>B721895E-F753-43C7-BC3E-95FB04D64CFF</gtr:id><gtr:outcomeId>r-2609967554.5561757774a251a</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Education,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4C69C7FE-B7A4-4243-B867-86E59D2FEF24</gtr:id><gtr:title>Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65abcf4c7c04255298e26cfeaffc0e00"><gtr:id>65abcf4c7c04255298e26cfeaffc0e00</gtr:id><gtr:otherNames>Jankovich JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a7c13cc20bdf4.33790421</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G530468/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>